May 19, 2015 by Fink Densford
ConMed, in the middle of an under-appreciated turnaround, could be poised to augment its growth via selective acquisitions, according to Leerink Partners analyst Richard Newitter.
Newitter, who upgraded CNMD shares to “outperform” and boosted the price target to $64 from $60, wrote in a note to investors yesterday that ConMed’s “turnaround and 2-3 yr sales/EPS growth prospects are underappreciated.” Read more
May 20, 2015 by Mark Hollmer
Baxter said it plans to boost its sales and margin growth after the planned July 1 spinout of its biopharmaceutical division as Baxalta.
“The spin-off provides us with flexibility to bring our product portfolio to market more effectively and capitalize on global opportunities and emerging trends to address patient needs while enhancing profitability,” chairman & CEO Robert Parkinson Jr. said in prepared remarks. Read more
May 26, 2015 by Fink Densford
Sorin Group said shareholders met today and approved its upcoming merger with Cyberonics.
The deal, which is slated to bring together global leaders in neuromodulation and cardiac surgery with a combined equity value of $2.7 billion, is expected to close by the end of the 3rd quarter. Read more